Source: Targeted Oncology, March 2017
The first-in-class IDO1 inhibitor epacadostat (INCB024360), currently being investigated in combination with the PD-1 inhibitor pembrolizumab (Keytruda), could be an exciting new FDA approval for patients with stage III/IV unresectable or metastatic melanoma (NCT02752074) and a less toxic frontline standard of care for these patients, according to Thomas F. Gajewski, MD, PhD.
The combination is being explored in the ongoing phase III KEYNOTE-252/ECHO-301 trial, in which 600 patients across more than 120 locations will be randomized to the novel combination or pembrolizumab plus placebo (NCT02752074).
Phase I findings for the combination presented at the 2016 ESMO Congress demonstrated that 11 of 19 evaluable treatment-naïve patients achieved an objective response (58%), including 5 patients (26%) with a complete response and 6 participants (32%) with a partial response. The disease control rate was 74%.read the original full article